XML 63 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:    
Research and development $ 15,859 $ 8,350
General and administrative 22,216 5,843
Total operating expenses 38,075 14,193
Loss from operations (38,075) (14,193)
Change in fair value of warrant liability 1,146 3,784
Change in fair value of convertible promissory notes 2,022 2,745
Interest on convertible promissory notes payable (110) (132)
Other income (expense), net 660 (28)
Total other income (expense), net 3,718 6,369
Net loss (34,357) (7,824) [1]
Deemed distribution to convertible promissory note holders 0 (1,318)
Net loss attributable to common stockholders $ (34,357) $ (9,142)
Net loss per share—basic $ (7.66) $ (111.16)
Net loss per share—diluted $ (7.66) $ (111.16)
Weighted-average number of shares outstanding used in computing net loss per share—basic 4,486,258 82,245
Weighted-average number of shares outstanding used in computing net loss per share—diluted 4,486,258 82,245
[1]

(1) Retroactively restated for the reverse recapitalization as described in Note 2.